Related references
Note: Only part of the references are listed.Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studies
Shrinidh A. Joshi et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2010)
Pharmaceutical stability aspects of nanomedicines
Madaswamy S. Muthu et al.
NANOMEDICINE (2009)
Brain targeting PBCA nanoparticles and the blood-brain barrier
B. Wilson
NANOMEDICINE (2009)
Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease
Barnabas Wilson et al.
BRAIN RESEARCH (2008)
Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles
Barnabas Wilson et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2008)
Development of a smart nano-vehicle to target cerebrovascular amyloid deposits and brain parenchymal plaques observed in Alzheimer's disease and cerebral amyloid angiopathy
Edward K. Agyare et al.
PHARMACEUTICAL RESEARCH (2008)
Drug development for CNS disorders: strategies for balancing risk and reducing attrition
Menelas N. Pangalos et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Forecasting the global burden of Alzheimer's disease
Ron Brookmeyer et al.
ALZHEIMERS & DEMENTIA (2007)
Global prevalence of dementia: a Delphi consensus study
CP Ferri et al.
LANCET (2005)
Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases
ZR Cui et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2005)
Share Paper
